Lipid-Based Liquid Crystalline Nanoparticles Facilitate Cytosolic Delivery of siRNA via Structural Transformation

Nano Lett. 2018 Apr 11;18(4):2411-2419. doi: 10.1021/acs.nanolett.7b05430. Epub 2018 Mar 23.

Abstract

RNA interference (RNAi) technology has shown great promise for the treatment of cancer and other genetic disorders. Despite the efforts to increase the target tissue distribution, the safe and effective delivery of siRNA to the diseased cells with sufficient cytosolic transport is another critical factor for successful RNAi clinical application. Here, the constructed lipid-based liquid crystalline nanoparticles, called nano-Transformers, can transform thestructure in the intracellular acidic environment and perform high-efficient siRNA delivery for cancer treatment. The developed nano-Transformers have satisfactory siRNA loading efficiency and low cytotoxicity. Different from the traditional cationic nanocarriers, the endosomal membrane fusion induced by the conformational transition of lipids contributes to the easy dissociation of siRNA from nanocarriers and direct release of free siRNA into cytoplasm. We show that transfection with cyclin-dependent kinase 1 (CDK1)-siRNA-loaded nano-Transformers causes up to 95% reduction of relevant mRNA in vitro and greatly inhibits the tumor growth without causing any immunogenic response in vivo. This work highlights that the lipid-based nano-Transformers may become the next generation of siRNA delivery system with higher efficacy and improved safety profiles.

Keywords: Lipids; endosomal escape; liquid crystalline nanoparticles; siRNA delivery; synthetic lethality.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CDC2 Protein Kinase / genetics
  • Hep G2 Cells
  • Humans
  • Lipids / chemistry*
  • Liquid Crystals / chemistry*
  • Mice, Inbred BALB C
  • Mice, Nude
  • Nanoparticles / chemistry*
  • Neoplasms / genetics
  • Neoplasms / therapy
  • RNA Interference*
  • RNA, Messenger / genetics
  • RNA, Small Interfering / administration & dosage*
  • RNA, Small Interfering / genetics
  • RNAi Therapeutics

Substances

  • Lipids
  • RNA, Messenger
  • RNA, Small Interfering
  • CDC2 Protein Kinase